| |
| |
|
| Insider
Information: |
Posard Matthew L. |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
386,328 |
|
|
Indirect Shares
|
100,000 |
|
|
| Direct
Value |
$9,267,407 |
|
|
|
Indirect Value
|
$277,000 |
|
|
| Total
Shares |
486,328 |
|
|
| Total
Value |
$9,544,407 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-3.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -78.2%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Illumina Inc |
ILMN |
Sr VP & General Manager |
2013-05-30 |
30,858 |
|
0 |
Premium* |
|
|
Halozyme Therapeutics Inc |
HALO |
|
2024-04-25 |
119,755 |
2013-03-27 |
0 |
Premium* |
|
|
Cardiff Oncology Inc |
CRDF |
Officer |
2015-08-21 |
15,000 |
|
0 |
Premium* |
|
|
Dermtech Ord Shs |
DMTK |
Director |
2023-06-01 |
158,215 |
|
0 |
Premium* |
|
|
Talis Biomedical Corp |
TLIS |
Director |
2021-02-17 |
62,500 |
2021-02-17 |
0 |
Premium* |
|
|
Nautilus Biotechnology, Inc |
NAUT |
Director |
|
0 |
2021-06-09 |
100,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TLIS |
Talis Biomedical Corp |
Director |
– • – |
2021-02-17 |
4 |
B |
$16.00 |
$1,000,000 |
D/D |
62,500 |
62,500 |
2.39 |
- |
|
| NAUT |
Nautilus Biotechnology, I... |
Director |
– • – |
2021-06-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
100,000 |
|
% |
|
| ILMN |
Illumina Inc |
Sr VP & GM, Consumer GenomicsO |
• – – |
2012-02-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
16,807 |
|
- |
|
| ILMN |
Illumina Inc |
Sr VP & GM, Consumer Genomics |
• – – |
2012-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
12,292 |
29,099 |
0 |
- |
|
| ILMN |
Illumina Inc |
Sr VP & General Manager |
• – – |
2012-08-01 |
5 |
A |
$35.62 |
$926 |
D/D |
26 |
29,125 |
0 |
- |
|
| ILMN |
Illumina Inc |
Sr VP & General Manager |
• – – |
2013-01-27 |
4 |
D |
$51.62 |
$34,172 |
D/D |
(662) |
28,437 |
0 |
- |
|
| ILMN |
Illumina Inc |
Sr VP & General Manager |
• – – |
2013-01-28 |
4 |
D |
$51.62 |
$37,579 |
D/D |
(728) |
27,709 |
0 |
- |
|
| ILMN |
Illumina Inc |
Sr VP & General Manager |
• – – |
2013-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
4,458 |
32,167 |
0 |
- |
|
| ILMN |
Illumina Inc |
Sr VP & General Manager |
• – – |
2013-01-31 |
4 |
D |
$50.63 |
$15,189 |
D/D |
(300) |
31,867 |
0 |
- |
|
| ILMN |
Illumina Inc |
Sr VP & General Manager |
• – – |
2013-03-08 |
4 |
D |
$53.77 |
$87,322 |
D/D |
(1,624) |
30,858 |
0 |
- |
|
| ILMN |
Illumina Inc |
Sr VP & General Manager |
• – – |
2013-04-11 |
4 |
AS |
$57.95 |
$2,795,044 |
D/D |
(48,232) |
30,858 |
0 |
- |
|
| ILMN |
Illumina Inc |
Sr VP & General Manager |
• – – |
2013-04-11 |
4 |
OE |
$20.04 |
$1,468,583 |
D/D |
48,232 |
42,408 |
0 |
- |
|
| ILMN |
Illumina Inc |
Sr VP & General Manager |
• – – |
2013-05-30 |
4 |
AS |
$70.80 |
$200,789 |
D/D |
(2,836) |
30,858 |
0 |
- |
|
| ILMN |
Illumina Inc |
Sr VP & General Manager |
• – – |
2013-05-30 |
4 |
OE |
$37.04 |
$105,045 |
D/D |
2,836 |
33,694 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • – |
2013-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • – |
2014-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
24,876 |
44,876 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • – |
2015-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
13,175 |
58,051 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • – |
2016-05-04 |
4 |
A |
$0.00 |
$0 |
D/D |
20,202 |
78,253 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • – |
2017-05-04 |
4 |
A |
$0.00 |
$0 |
D/D |
14,135 |
92,388 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • – |
2018-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
10,363 |
102,751 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • – |
2019-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,173 |
114,924 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • – |
2020-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
8,829 |
123,753 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
Director |
– • – |
2021-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
5,230 |
128,983 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
|
– • – |
2022-12-02 |
4 |
S |
$58.80 |
$588,000 |
D/D |
(10,000) |
125,189 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
|
– • – |
2022-12-05 |
4 |
S |
$55.74 |
$557,370 |
D/D |
(10,000) |
115,189 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
